Program
serplulimab
Also written as “HLX10”, “Serplulimab + chemotherapy (carboplatin-etoposide)” and “HLX10+chemo”.
Its studies are mostly in Small Cell Lung Carcinoma · Colorectal Neoplasms · Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 3 companies.
Drug pageSerplulimab: every studyAll 107 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharmaits history only | 2512 open or running | phase 3since May 6, 2019 | Nov 19, 2018 | none ahead |
| Guangzhou FineImmune Biotechnologyits history only | 11 open or running | phase 1since Mar 4, 2024 | Mar 4, 2024 | none ahead |
| Henlixits history only | 10 open or running | phase 1since Mar 11, 2018 | Mar 11, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 13 earlier studies, Mar 11, 2018 to Sep 7, 2020.
- Jun 9, 2019Named serplulimabINNProposed as its International Nonproprietary Name in WHO's List 121
- Mar 17, 2021Phase 3 study in Uterine Cervical NeoplasmsFosun Pharma · NCT04806945 · China
- Jul 20, 2021Phase 2 study in Squamous Non-small-cell Lung CancerFosun Pharma · NCT04976647 · 156 enrolled · China
- Jan 22, 2022Phase 2 study in ESCC or Esophageal Adenosquamous CarcinomaFosun Pharma · NCT05221658 · 60 planned · China
- Feb 16, 2022Phase 2 study in Stomach NeoplasmsFosun Pharma · NCT05246982 · 40 enrolled · China
- Apr 25, 2022Phase 3 study in Small Cell Lung CarcinomaFosun Pharma · NCT05353257 · 511 enrolled · United States, Austria, China and more
- Apr 26, 2022Phase 2 study in Small Cell Lung CarcinomaFosun Pharma · NCT05354700 · 20 enrolled · China
- May 23, 2022Phase 1 study in Adult Solid TumorFosun Pharma · NCT05400265 · 9 enrolled · China
- Jun 29, 2022Phase 1 study in Solid Tumor, AdultFosun Pharma · NCT05442996 · 30 planned
- Jul 6, 2022Phase 1 study in Advanced or Metastatic Solid TumorsFosun Pharma · NCT05483530 · 20 enrolled · Australia
- Jul 11, 2022Phase 2 study in Extensive Stage Small Cell Lung CancerFosun Pharma · NCT05468489 · 200 enrolled · United States
- Oct 14, 2022Phase 2 study in Colorectal Cancer MetastaticFosun Pharma · NCT05584137 · 2 enrolled · China
- Nov 15, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungFosun Pharma · NCT05641493 · 49 planned · China
- Mar 4, 2024Guangzhou FineImmune Biotechnology’s first study: phase 1 study in Drug-Related Side Effects and Adverse ReactionsNew to Guangzhou FineImmune BiotechnologyGuangzhou FineImmune Biotechnology · NCT06302062 · 23 planned · China
- Jan 22, 2025Phase 2 study in SCLC, Extensive StageFosun Pharma · NCT06812260 · 26 enrolled · Japan
TargetBeta
“A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06812260SCLC, Extensive Stage · Japan | 2 | Active, not recruiting | Fosun Pharma | Oct 22, 2026 | 26 |
| NCT06302062Drug-Related Side Effects and Adverse Reactions · China | 1 | Recruiting | Guangzhou FineImmune Biotechnology | Dec 30, 2025 | 23 |
| NCT05641493Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Fosun Pharma | Mar 4, 2025 | 49 |
| NCT05584137Colorectal Cancer Metastatic · China | 2 | Terminated | Fosun Pharma | Dec 31, 2023 | 2 |
| NCT05468489Extensive Stage Small Cell Lung Cancer · United States | 2 | Active, not recruiting | Fosun Pharma | Feb 28, 2026 | 200 |
| NCT05483530Advanced or Metastatic Solid Tumors · Australia | 1 | Active, not recruiting | Fosun Pharma | Dec 2024 | 20 |
| NCT05442996Solid Tumor, Adult | 1 | Not yet recruiting | Fosun Pharma | Apr 22, 2024 | 30 |
| NCT05400265Adult Solid Tumor · China | 1 | Completed | Fosun Pharma | Aug 31, 2023 | 9 |
| NCT05354700Small Cell Lung Carcinoma · China | 2 | UNKNOWN | Fosun Pharma | Mar 29, 2024 | 20 |
| NCT05353257Small Cell Lung Carcinoma · United States, Austria, China and more | 3 | Active, not recruiting | Fosun Pharma | Jun 30, 2026 | 511 |
| NCT05246982Stomach Neoplasms · China | 2 | UNKNOWN | Fosun Pharma | Dec 20, 2023 | 40 |
| NCT05221658ESCC or Esophageal Adenosquamous Carcinoma · China | 2 | Recruiting | Fosun Pharma | Jun 30, 2024 | 60 |
| NCT04976647Squamous Non-small-cell Lung Cancer · China | 2 | UNKNOWN | Fosun Pharma | Jan 30, 2023 | 156 |
| NCT04806945Uterine Cervical Neoplasms · China | 3 | Withdrawn | Fosun Pharma | Feb 15, 2024 | 0 |
| NCT04547166Colorectal Neoplasms · China, Japan | 3 | Recruiting | Fosun Pharma | Sep 24, 2025 | 568 |
| NCT04465734Carcinoma, Hepatocellular · China | 3 | Withdrawn | Fosun Pharma | Oct 15, 2023 | 0 |
| NCT04301739Triple Negative Breast Neoplasms | 3 | Not yet recruiting | Fosun Pharma | Sep 7, 2022 | 522 |
| NCT04150575Uterine Cervical Neoplasms · China | 2 | UNKNOWN | Fosun Pharma | Jun 15, 2022 | 21 |
| NCT04139135Stomach Neoplasms · China | 3 | UNKNOWN | Fosun Pharma | Oct 2023 | 642 |
| NCT04063163Small Cell Lung Carcinoma · Georgia, Poland, Russia and more | 3 | Completed | Fosun Pharma | May 7, 2024 | 585 |
| NCT04033354Neoplasm Metastasis · United States, China, Georgia and more | 3 | Active, not recruiting | Fosun Pharma | Dec 30, 2023 | 537 |
| NCT03973112Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Fosun Pharma | Jun 15, 2022 | 123 |
| NCT03958890Esophageal Squamous Cell Carcinoma · China | 3 | UNKNOWN | Fosun Pharma | Apr 30, 2023 | 489 |
| NCT03952403Carcinoma · China | 3 | Active, not recruiting | Fosun Pharma | Oct 1, 2023 | 643 |
| NCT03941574MSI-H Solid Malignant Tumor · China | 2 | Recruiting | Fosun Pharma | May 30, 2024 | 108 |
| NCT03757936Solid Tumor · China | 1 | UNKNOWN | Fosun Pharma | Sep 27, 2019 | 30 |
| NCT03468751Neoplasm Metastasis · Taiwan | 1 | UNKNOWN | Henlix | Jun 30, 2020 | 30 |
How it is read
Names in the registry
- “HLX10”, 15 entries
- “Serplulimab + chemotherapy (carboplatin-etoposide)”, 1 entry
- “HLX10+chemo”, 1 entry
- “Serplulimab Injection”, 1 entry
- “HLX60 combined with HLX10”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
- Colorectal Neoplasms, 2 studies
- Neoplasm Metastasis, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Stomach Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.